Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 9/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498203 | 1.00 | GPR34 (0.58) | GPR34PTPN1GPR132PPARGMME | |
| SCHEMBL3500047 | 0.93 | GPR34 (0.49) | GPR34PTPN1PPARG | |
| SCHEMBL3500044 | 0.93 | GPR34 (0.49) | GPR34PTPN1PPARG | |
| SCHEMBL3499375 | 0.86 | GPR34 (0.56) | GPR34PTPN1GPR132PPARGMME | |
| SCHEMBL3499379 | 0.86 | GPR34 (0.56) | GPR34PTPN1GPR132PPARGMME | |
| SCHEMBL3498177 | 0.85 | GPR34 (0.65) | GPR34PTPN1GPR132PPARGMME | |
| SCHEMBL3498179 | 0.85 | GPR34 (0.65) | GPR34PTPN1GPR132PPARGMME | |
| SCHEMBL3499888 | 0.83 | GPR34 (0.58) | GPR34PTPN1GPR132PPARGMME | |
| SCHEMBL3499890 | 0.83 | GPR34 (0.58) | GPR34PTPN1GPR132PPARGMME | |
| SCHEMBL3509897 | 0.83 | GPR34 (0.56) | GPR34PTPN1GPR132PPARGMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | GPR34 1/4885PTPN1 3494/4885GPR132 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.